Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. William Gradishar

Breast Oncology · NU

View

Dr. Jame Abraham

Breast Oncology · Cleveland Clinic

View

Dr. Azka Ali

Breast Oncology · Cleveland Clinic Lerner

View

Dr. Amy Comander

Breast Oncology · PHS

View

Dr. Paolo Tarantino

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Anastasia Martynova

Breast Oncology · USC

View

Dr. Rani Bansal

Breast Oncology · Duke

View

Dr. Gilbert Bader

Breast Oncology · OSUMC

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    AEDr. Ahmed Elkhanany

    Dr. Ahmed Elkhanany

    Hematology & Oncology · Breast Oncology
    Baylor College of Medicine
    ahmedelkhanany
    Houston, TX, USA

    Research

    CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them?

    2025

    Via International Journal of Molecular Sciences

    Research

    Increasing Inclusion and Equity for Black Women in Breast Cancer Clinical Trials

    2024

    Via Clinical Advances in Hematology & Oncology

    Dec 9, 2024Journal Article

    Therapeutic Clinical Trial Eligibility and Enrollment among Women with Breast Cancer: Implications for Understanding Trial Disparities.

    ​
    ​

    Written by 2 Roon authors & 8 others

    Via Annals of Surgical Oncology

    Research

    A Phase I/II Study of Preoperative Letrozole, Everolimus, and Carotuximab in Stage 2 and 3 Hormone Receptor-Positive and Her2-Negative Breast Cancer

    2023

    Via Breast Cancer Research and Treatment

    Research

    Mutations in Homologous Recombination Genes and Loss of Heterozygosity Status in Advanced-Stage Breast Carcinoma

    2023

    Via Cancers

    Research

    Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model

    2023

    Via JCO Clinical Cancer Informatics

    Research

    Open-label, Phase II, Multicenter Study of Lasofoxifene plus Abemaciclib for Treating Women with Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation after Disease Progression on Prior Therapies: ELAINE 2

    2023

    Via Annals of Oncology

    Research

    Detection of Microsatellite Instability High (MSI-H) Status by Targeted Plasma-Based Genotyping in Metastatic Breast Cancer

    2022

    Via NPJ Breast Cancer

    Research

    Effect of Prior Treatments on Post-CDK 4/6 Inhibitor Survival in Hormone Receptor-Positive Breast Cancer

    2022

    Via Breast Cancer Research and Treatment

    Research

    Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion

    2021

    Via Journal of the National Cancer Institute

    Research

    Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

    2021

    Via Journal of the National Comprehensive Cancer Network

    Research

    Disparities in Breast Cancer Associated With African American Identity

    2021

    Via American Society of Clinical Oncology Educational Book

    Research

    NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020

    2020

    Via Journal of the National Comprehensive Cancer Network

    Research

    Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer

    2020

    Via International Journal of Molecular Sciences

    Research

    Primary and Secondary Breast Angiosarcoma: Single Center Report and a Meta-Analysis

    2019

    Via Breast Cancer Research and Treatment